The role of capecitabine in the treatment of colorectal cancer in the elderly

Lara Maria Pasetto, Silvio Monfardini

Research output: Contribution to journalArticle

Abstract

To overcome 5-Fluorouracil (5FU) infusion-related problems, oral 5FUprecursors and inhibitors of 5FU degradation have been developed. Capecitabine is one of these new oral fluoropyrimidines. Capecitabine treatment of advanced colorectal carcinoma, when compared to 5FU, results in superior response rates (26.6% versus 17.9%, p=0.013), equivalent times to progression and survival, and improved safety, including less stomatitis and myelosuppression. The benefits are principally derived from the avoidance of hospital visits for intravenous drug administration, less expensive drug therapy for the treatment of toxic side-effects, and fewer treatment-related hospitalisations required during the course of therapy for adverse drug reactions. In this review, the use of capecitabine, alone or in association with other drugs, in neoadjuvant, adjuvant and metastatic settings, was analysed in a selected group of elderly patients (≥70 years old) affected by colorectal cancer.

Original languageEnglish
Pages (from-to)2381-2386
Number of pages6
JournalAnticancer Research
Volume26
Issue number3 B
Publication statusPublished - May 2006

Fingerprint

Colorectal Neoplasms
Fluorouracil
Stomatitis
Poisons
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Intravenous Administration
Hospitalization
Safety
Drug Therapy
Survival
Capecitabine

Keywords

  • Capecitabine
  • Colorectal cancer
  • Elderly
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pasetto, L. M., & Monfardini, S. (2006). The role of capecitabine in the treatment of colorectal cancer in the elderly. Anticancer Research, 26(3 B), 2381-2386.

The role of capecitabine in the treatment of colorectal cancer in the elderly. / Pasetto, Lara Maria; Monfardini, Silvio.

In: Anticancer Research, Vol. 26, No. 3 B, 05.2006, p. 2381-2386.

Research output: Contribution to journalArticle

Pasetto, LM & Monfardini, S 2006, 'The role of capecitabine in the treatment of colorectal cancer in the elderly', Anticancer Research, vol. 26, no. 3 B, pp. 2381-2386.
Pasetto, Lara Maria ; Monfardini, Silvio. / The role of capecitabine in the treatment of colorectal cancer in the elderly. In: Anticancer Research. 2006 ; Vol. 26, No. 3 B. pp. 2381-2386.
@article{9eb17251b3804222a59bf7abc05df3d1,
title = "The role of capecitabine in the treatment of colorectal cancer in the elderly",
abstract = "To overcome 5-Fluorouracil (5FU) infusion-related problems, oral 5FUprecursors and inhibitors of 5FU degradation have been developed. Capecitabine is one of these new oral fluoropyrimidines. Capecitabine treatment of advanced colorectal carcinoma, when compared to 5FU, results in superior response rates (26.6{\%} versus 17.9{\%}, p=0.013), equivalent times to progression and survival, and improved safety, including less stomatitis and myelosuppression. The benefits are principally derived from the avoidance of hospital visits for intravenous drug administration, less expensive drug therapy for the treatment of toxic side-effects, and fewer treatment-related hospitalisations required during the course of therapy for adverse drug reactions. In this review, the use of capecitabine, alone or in association with other drugs, in neoadjuvant, adjuvant and metastatic settings, was analysed in a selected group of elderly patients (≥70 years old) affected by colorectal cancer.",
keywords = "Capecitabine, Colorectal cancer, Elderly, Review",
author = "Pasetto, {Lara Maria} and Silvio Monfardini",
year = "2006",
month = "5",
language = "English",
volume = "26",
pages = "2381--2386",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - The role of capecitabine in the treatment of colorectal cancer in the elderly

AU - Pasetto, Lara Maria

AU - Monfardini, Silvio

PY - 2006/5

Y1 - 2006/5

N2 - To overcome 5-Fluorouracil (5FU) infusion-related problems, oral 5FUprecursors and inhibitors of 5FU degradation have been developed. Capecitabine is one of these new oral fluoropyrimidines. Capecitabine treatment of advanced colorectal carcinoma, when compared to 5FU, results in superior response rates (26.6% versus 17.9%, p=0.013), equivalent times to progression and survival, and improved safety, including less stomatitis and myelosuppression. The benefits are principally derived from the avoidance of hospital visits for intravenous drug administration, less expensive drug therapy for the treatment of toxic side-effects, and fewer treatment-related hospitalisations required during the course of therapy for adverse drug reactions. In this review, the use of capecitabine, alone or in association with other drugs, in neoadjuvant, adjuvant and metastatic settings, was analysed in a selected group of elderly patients (≥70 years old) affected by colorectal cancer.

AB - To overcome 5-Fluorouracil (5FU) infusion-related problems, oral 5FUprecursors and inhibitors of 5FU degradation have been developed. Capecitabine is one of these new oral fluoropyrimidines. Capecitabine treatment of advanced colorectal carcinoma, when compared to 5FU, results in superior response rates (26.6% versus 17.9%, p=0.013), equivalent times to progression and survival, and improved safety, including less stomatitis and myelosuppression. The benefits are principally derived from the avoidance of hospital visits for intravenous drug administration, less expensive drug therapy for the treatment of toxic side-effects, and fewer treatment-related hospitalisations required during the course of therapy for adverse drug reactions. In this review, the use of capecitabine, alone or in association with other drugs, in neoadjuvant, adjuvant and metastatic settings, was analysed in a selected group of elderly patients (≥70 years old) affected by colorectal cancer.

KW - Capecitabine

KW - Colorectal cancer

KW - Elderly

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=33745563493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745563493&partnerID=8YFLogxK

M3 - Article

C2 - 16821620

AN - SCOPUS:33745563493

VL - 26

SP - 2381

EP - 2386

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -